Supplemental Table 2. Response after Six Cycles According to Age.

Response[1]	Age ≤ 60 years	Age > 60
Overall response, n (%)		
CR/PR	14 (74)	13 (65)
SD	0 (0)	0
POD	3 (16)	2 (10)
Discontinued for toxicity (prior to completion of six cycles)	2 (11)	5 (25)
Objective response rate, n (%)	14 (74)	20 (68)

[1]Responses to induction are shown for patients evaluable for efficacy who completed six cycles of induction therapy.

Supplemental Table 3. Safety.

Adverse Events	All grade, n (%)	Grade 3/4, n (%)
Hematologic events		
Neutropenia	28 (70)	27 (68)
Leukopenia	27 (68)	25 (63)
Anemia	23 (58)	17 (43)
Thrombocytopenia	21 (53)	17 (43)
Lymphopenia	20 (50)	18 (45)
Febrile neutropenia	15 (38)	15 (38)
Non-hematologic events		
Fatigue	33 (83)	1 (3)
Alopecia	24 (60)	0 (0)
Nausea	18 (45)	1 (3)
Diarrhea	17 (43)	3 (8)
Peripheral sensory neuropathy	14 (35)	2 (5)
Constipation	13 (33)	0 (0)
Anorexia	11 (28)	1 (3)
Dizziness	11 (28)	0 (0)
Vomiting	11 (28)	1 (3)
Mucositis	10 (25)	1 (3)
Cough	9 (23)	0 (0)
Fever	9 (23)	0 (0)
Rash, maculopapular	9 (23)	1 (3)
Abdominal pain	8 (20)	0 (0)
Hypotension	8 (20)	1 (3)
Anxiety	6 (15)	1 (3)
Back pain	6 (15)	1 (3)
Dyspnea	6 (15)	1 (3)
Headache	6 (15)	0 (0)
Pain	6 (15)	0 (0)

All causality adverse events occurring in ≥ 15% of patients